Reck M, Ciuleanu TE, Schenker M, Bordenave S, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer 2024;211:114296.
PMID: 39270380